Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.60 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.60 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.60 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | CCKAR | P32238 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP14 | P50281 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PYGL | P06737 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446970 | 1.00 | HSPA5 (0.60) | HSPA5HSPA8HSPA9HSPA2DRD2 | |
| SCHEMBL8670229 | 0.86 | CCKAR (0.77) | DRD2CCKARLMNANPC1RAB9A | |
| SCHEMBL8670236 | 0.86 | CCKAR (0.77) | DRD2CCKARLMNANPC1RAB9A | |
| SCHEMBL13753482 | 0.84 | DRD2 (0.64) | HSPA5HSPA8HSPA9HSPA2DRD2 | |
| SCHEMBL29949076 | 0.84 | DRD2 (0.68) | DRD2CCKARLMNANPC1RAB9A | |
| SCHEMBL13753384 | 0.84 | DRD2 (0.68) | DRD2CCKARLMNANPC1RAB9A | |
| SCHEMBL24380184 | 0.82 | DRD2 (0.61) | HSPA5HSPA8HSPA9HSPA2DRD2 | |
| SCHEMBL19476075 | 0.82 | MEN1 (0.64) | DRD2CCKARLMNANPC1RAB9A | |
| SCHEMBL23722653 | 0.82 | DRD2 (0.61) | HSPA5HSPA8HSPA9HSPA2DRD2 | |
| SCHEMBL6883379 | 0.82 | MEN1 (0.64) | DRD2CCKARLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | HSPA5 2590/4885HSPA8 2139/4885HSPA9 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.